Is there a Bearish outlook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo
Investors sentiment increased to 1.43 in Q1 2019. Its up 0.35, from 1.08 in 2018Q4. It is positive, as 23 investors sold Sarepta Therapeutics, Inc. shares while 88 reduced holdings. 57 funds opened positions while 102 raised stakes. 74.26 million shares or 13.02% more from 65.70 million shares in 2018Q4 were reported.
United Automobile Association stated it has 11,215 shares or 0% of all its holdings. Cadian Mgmt Ltd Partnership owns 2.84% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 610,546 shares. Macquarie reported 0.07% stake. Sigma Planning holds 0.15% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 21,741 shares. Sectoral Asset Mgmt invested in 128,098 shares or 1.84% of the stock. Neuberger Berman Lc reported 60,000 shares. Sg Americas Secs Limited Com owns 5,511 shares. 10,000 are held by Apis Cap Advsrs Ltd Limited Liability Company. Reilly Advsr Limited has 500 shares for 0.01% of their portfolio. Moreover, Martingale Asset Mgmt Lp has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 3,703 shares. Profund Advsr Lc invested in 0.11% or 18,466 shares. 3,300 are held by Baldwin Invest Management Ltd Liability Corporation. Citigroup accumulated 92,625 shares. Point72 Asset Management L P holds 0.14% or 260,790 shares in its portfolio. Legal & General Group Incorporated Public Ltd Co stated it has 37,431 shares.

Since August 12, 2019, it had 2 buys, and 0 sales for $2.16 million activity. Another trade for 16,252 shares valued at $2.00 million was made by INGRAM DOUGLAS S on Monday, August 12.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $270 highest and $16500 lowest target. $203.56’s average target is 66.89% above currents $121.97 stock price. Sarepta Therapeutics had 33 analyst reports since February 19, 2019 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $231 target in Thursday, February 28 report. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, February 28. Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, February 27 with “Buy” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Friday, February 22 by Cantor Fitzgerald. On Friday, June 21 the stock rating was maintained by Piper Jaffray with “Buy”. Cantor Fitzgerald maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Tuesday, June 25. Cantor Fitzgerald has “Buy” rating and $231 target. On Thursday, February 28 the stock rating was maintained by Nomura with “Buy”. SunTrust maintained it with “Buy” rating and $176 target in Wednesday, February 27 report. As per Thursday, February 28, the company rating was maintained by Janney Capital. The firm has “Buy” rating given on Monday, March 25 by H.C. Wainwright. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

09/07/2019 Broker: Inc. – Common Stock Rating: Morgan Stanley New Target: $165.0000 220.0000
01/07/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $188.0000 220.0000
25/06/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $231 Maintain
21/06/2019 Broker: Piper Jaffray Rating: Buy New Target: $208 Maintain
16/05/2019 Broker: Inc. – Common Stock Rating: Citigroup New Target: $201.0000 190.0000
09/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $191.0000 188.0000
26/04/2019 Broker: BidaskScore Rating: Hold Upgrade
12/04/2019 Broker: Evercore Rating: Outperform New Target: $175 Initiates Coverage On
26/03/2019 Broker: Citigroup Rating: Buy New Target: $201 Maintain
25/03/2019 Broker: J.P. Morgan Rating: Buy Maintain

The stock decreased 1.31% or $1.62 during the last trading session, reaching $121.97. About 962,745 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since August 15, 2018 and is uptrending. It has outperformed by 29.09% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.07 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Benzinga.com which released: “Barron’s On: Pharma’s Big Hope – Benzinga” on March 03, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT – Nasdaq” published on March 06, 2019, Seekingalpha.com published: “Sarepta Therapeutics EPS beats by $0.42, beats on revenue – Seeking Alpha” on August 07, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Health Care Sector Update for 03/25/2019: SRPT,NK,MDWD – Nasdaq” published on March 25, 2019 as well as Finance.Yahoo.com‘s news article titled: “Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today – Yahoo Finance” with publication date: March 06, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.